

Biofilm formation by *Pseudomonas aeruginosa*: role of the C₄-HSL cell-to-cell signal and inhibition by azithromycin

Sabine Favre-Bonté*, Thilo Köhler and Christian Van Delden†

Department of Genetics and Microbiology, University of Geneva, CMU, 1, rue Michel-Servet, CH-1211 Geneva 4, Switzerland

Received 6 February 2003; returned 6 April 2003; revised 19 June 2003; accepted 30 June 2003

Objectives: In *Pseudomonas aeruginosa*, biofilm formation is controlled by a cell-to-cell signalling circuit relying on the secretion of 3-oxo-C₁₂-HSL and C₄-HSL. Previous studies suggested that C₄-HSL plays no significant role in biofilm formation. However the wild-type PAO1 strain PAO-BI, used as a control in these studies is itself impaired in the production of C₄-HSL. We wondered therefore whether the role of C₄-HSL in biofilm formation might have been underestimated, and whether azithromycin inhibits biofilm formation by interfering with cell-to-cell signalling.

Methods: We used isogenic mutants of wild-type PAO1 strains PAO-BI and PT5 in a static biofilm model. Biofilm formation was quantified using Crystal Violet staining and exopolysaccharide measurements.

Results: Wild-type strain PAO-BI, as a result of its reduced C₄-HSL secretion, produced 40% less biofilm compared with the wild-type PAO1 strain PT5. Using isogenic mutants of strain PT5 we have shown that whereas a *lasI* mutant (deficient in 3-oxo-C₁₂-HSL) produced similar amounts of biofilm to the wild-type, a *rhII* mutant (deficient in C₄-HSL) produced 70% less biofilm. In the latter strain, biofilm formation could be restored by addition of exogenous C₄-HSL. Azithromycin, known to reduce the production of both 3-oxo-C₁₂-HSL and C₄-HSL, inhibited biofilm formation of wild-type PT5 by 45%. This inhibition could be reversed by the addition of both cell-to-cell signals.

Conclusions: Our results indicate that C₄-HSL also plays a significant role in biofilm formation. Furthermore, we demonstrate the potential of using cell-to-cell signalling blocking agents such as azithromycin to interfere with biofilm formation.

Keywords: quorum sensing, autoinducers, homoserine-lactones, 3-oxo-C₁₂-HSL

Introduction

The opportunistic pathogen *Pseudomonas aeruginosa* is responsible for severe ventilator-associated pneumonia (VAP) in intubated patients. In these patients, colonization of the upper respiratory tract by *P. aeruginosa*, which almost always precedes pneumonia, is related to the presence and duration of an endotracheal intubation. The colonization of inert surfaces by *P. aeruginosa* requires a sessile bacterial growth pattern, called a biofilm.¹ The acyl homoserine lactone based cell-to-cell signals (autoinducers, AHLs) 3-oxo-C₁₂-HSL and C₄-HSL participate in a cell-to-cell signalling (quorum-sensing) regulatory network that controls the production of several extra-cellular virulence factors and are important for biofilm formation.² Synthesis of these molecules depends on two autoinducer-synthase genes, *lasI* and *rhII*, respectively.² Both AHLs are produced *in vitro*

by *P. aeruginosa* isolates from chronically infected cystic fibrosis (CF) patients,³ *ex vivo* in sputum from CF patients infected by *P. aeruginosa*,⁴ as well as in lungs of mice chronically infected by *P. aeruginosa*.⁵ AHLs have been detected *in situ* on urethral catheters and *in vitro* using a *P. aeruginosa* biofilm model,⁶ as well as in lung secretions of CF patients.^{7,8} Based on studies using the wild-type PAO1 strain PAO-BI and its derived *lasI* mutant PAO-JP1, it has been shown that 3-oxo-C₁₂-HSL is required for biofilm differentiation.⁹ Using the same strain PAO-BI, it was observed that the autoinducer synthase gene *lasI*, required for 3-oxo-C₁₂-HSL production, is expressed in a large number of cells during the initial phase of biofilm development and that this number decreases progressively over time.¹⁰ In contrast, *rhII*, the autoinducer synthase gene required for C₄-HSL production, was expressed in fewer cells but remained constant over time. Based on these observations, it has

*Present address. UMR CNRS 5557-Ecologie Microbienne, Université Claude Bernard, Lyon 1, France.

†Corresponding author. Tel: +41-22-702-56-39; Fax: +41-22-702-57-02; E-mail: Christian.VanDelden@medecine.unige.ch

Inhibition of cell-to-cell signalling by azithromycin

Table 1. Bacterial strains and plasmids used in this study

Strain	Relevant characteristics	Source or reference
<i>E. coli</i>		
MG4λI ₁ 4	λ lysogen carrying a chromosomal <i>lasI::lacZ</i> fusion	40
<i>P. aeruginosa</i>		
PAO-BI	PAO1 wild-type (<i>nfxC</i>)	14
PAO-JP1	PAO-BI (<i>nfxC</i> , Δ <i>lasI</i>)	41
PT918	PAO-BI (<i>nfxC</i> , <i>mexE::ΩHg</i>)	this study
PDO100	PAO1 (<i>rhlI::Tn501</i>)	42
PAO-JP2	PDO100(Δ <i>lasI</i>)	41
PT5	PAO1 wild-type	14
PT466	PT5(Δ <i>lasI</i>)	18
PT454	PT5(Δ <i>rhlI</i>)	18
PT502	PT5(Δ <i>lasI</i> , Δ <i>rhlI</i>)	31
<i>Plasmids</i>		
pECP61.5	<i>rhlA'</i> - <i>lacZ</i> transcriptional fusion	41

been suggested that C₄-HSL might be of little importance in biofilm formation.¹⁰ This is surprising as it has recently been shown that *ex vivo*, *P. aeruginosa* isolates from CF patients grown in biofilm produce higher amounts of C₄-HSL compared with 3-oxo-C₁₂-HSL.⁴ It has also been suggested that this AHL production pattern could be used as a marker for *P. aeruginosa* growing in biofilm in CF patients.⁴ We have detected AHLs *in situ* directly in the lung tissue of CF patients infected by *P. aeruginosa* and found a similar elevated C₄-HSL/3-oxo-C₁₂-HSL ratio.¹¹ Moreover, the *rhl* cell-to-cell signalling system (dependent on the production of C₄-HSL) has been suggested to be important for survival of bacteria during the anaerobic biofilm mode of growth encountered in CF lung disease,¹² and rhamnolipids whose production is controlled by C₄-HSL² has been shown to be required for the maintenance of biofilm architecture.¹³ Together, these observations suggest that C₄-HSL might be more important for biofilm formation than previously thought.

It has been recently understood that wild-type PAO1 strains from various laboratories might differ in cell-to-cell signal production.¹⁴ In particular, strain PAO-BI produces less C₄-HSL than other PAO1 strains.¹⁴ We have recently described that the macrolide antibiotic azithromycin inhibits virulence factor production of *P. aeruginosa* by interfering with the cell-to-cell signalling circuit.¹⁵ We wondered whether the reduced production of C₄-HSL by strain PAO-BI might have affected previous biofilm studies using this strain as a control strain, and whether azithromycin affects biofilm formation by interfering with AHL production.

Materials and methods

Media, antibiotics and strains

Unless otherwise stated, bacteria were freshly streaked from frozen stocks onto LB-agar medium supplemented with antibiotics when appropriate. Liquid LB cultures, containing antibiotics when appropriate, were grown overnight at 37°C with agitation (250 rpm). Minimal AP medium supplemented with 0.3 M NaCl was used for biofilm growth experiments.¹⁶ Antimicrobials were supplied at the following concentrations: gentamicin (15 mg/L), tetracycline (50 mg/L), mercury chloride (12.5 mg/L). All chemicals and antimicrobials were purchased from

Sigma, except azithromycin which was kindly provided by Pfizer. The bacterial strains and their genetic linkage are presented in Table 1. To construct strain PT918 (PAO-BI *mexE::ΩHg*), the *mexE::ΩHg* mutation from strain PT121¹⁷ was transferred by transduction using phage E79tv2¹⁸ into strain PAO-BI.

Autoinducer measurements

For extraction of autoinducers from liquid cultures, bacterial strains were grown in LB medium until they reached stationary phase (6 h). Aliquots of filtered culture supernatants were subjected to two extractions by addition of one volume of acidified ethyl acetate (0.01% acetic acid). For extraction of autoinducers from biofilms, polyvinyl chloride (PVC) fragments on which biofilms had been formed were rinsed three times and immersed into 1 mL of 0.9% NaCl. One volume of acidified ethyl acetate was added and the mixture incubated in closed tubes at 4°C overnight. A second extraction was carried out for 1 h, and the two extracts were pooled. The extracted autoinducers were quantified using specific bioassays using *E. coli* MG4λI₁4 (pPCS1) for 3-oxo-C₁₂-HSL and *P. aeruginosa* PAO-JP2 (pECP61.5) for C₄-HSL as reporter strains.¹⁹ β-Galactosidase (β-gal) activity was determined as previously described.²⁰

Static biofilm formation assay

Sterile PVC strips of approximately 1 cm² were cut from original endotracheal devices (Mallinckrodt Inc., St Louis, MO, USA) and biofilm was allowed to develop under static conditions for 3 days as previously described.²¹ All PVC strips were weighed and experiments were standardized by weight. Bacterial strains were grown in LB medium for 6 h with agitation at 37°C. PVC strips were immersed in the bacterial culture medium for 1 h without agitation to allow bacteria to adhere. PVC strips were then transferred into AP medium and incubated for 3 days without agitation at 37°C. Azithromycin (2 mg/L) and/or autoinducers (10 μM each, once a day) were added as indicated. After the 3 day incubation period, the PVC strips were individually washed twice in 0.9% NaCl and subjected to biofilm measurements (see below). We had previously observed that initial growth of wild-type PT5 was slightly retarded in the presence of 2 mg/L azithromycin when grown under agitation in liquid media.¹⁵ This effect was restricted to early and mid-exponential growth phases, when quorum sensing is not yet active. In order to determine

whether this small delay could affect final growth in our 3 day static biofilm assay, we measured colony forming units (cfu) of strain PT5 grown without agitation after 3 days in the biofilm medium in the presence and absence of 2 mg/L azithromycin. Azithromycin did not affect the number of viable counts of wild-type strain PT5.

Crystal Violet staining and exopolysaccharide determinations

PVC strips, on which biofilm had developed, were incubated for 15 min in a Crystal Violet staining solution (0.1% in distilled water),²² and washed three times in distilled water. The stain was then dissolved in ethanol and absorbance was measured at 570 nm as previously described.²²

Exopolysaccharide determinations were carried out by total carbohydrate assays.²³ PVC strips were washed in 0.9% NaCl, and incubated in an equal volume of 5% phenol to which 5 volumes of H₂SO₄ containing hydrazine sulphate was added. The mixture was incubated for 1 h in the dark and absorbance was measured at 490 nm.

Results and discussion

Role of C₄-HSL and 3-oxo-C₁₂-HSL in total biofilm formation

Most *in vitro* studies have investigated the potential role of cell-to-cell signals in the formation of *P. aeruginosa* biofilm using a continuous flow system.^{9,10,24,25} In such bioreactors a constant medium flux brings new nutrients and eliminates metabolic products. These experimental conditions are therefore very different from *in vivo* situations such as biofilm formation on endotracheal intubation devices. Indeed the bacteria growing inside the secretions that accumulate above the cuff of intubation devices are in static growth conditions without regular change of their growth medium. We therefore decided to adopt a static *in vitro* biofilm model²¹ using sterile PVC strips derived from original intubation devices. Previous experiments, using continuous flow systems, have shown that the total amount of biofilm formed by the *lasI* mutant PAO-JP1 is not reduced compared with its parent strain.^{9,25} As experimental conditions greatly influence biofilm formation,²⁵ we first compared biofilm formation by mutant PAO-JP1 and its parent strain the PAO1 wild-type strain PAO-BI in our static biofilm assay. Biofilm measurements using Crystal Violet staining gave similar results for both strains (Figure 1a), confirming that the *lasI* mutation does not affect total biofilm formation in our biofilm model.

In previous studies, strain PAO-BI and its derived *lasI* mutant PAO-JP1, as well as the non-*nfxC* *rhlI* mutant PDO100, have been used to determine the respective roles of autoinducers in biofilm formation.^{9,10,24,25} Such studies have suggested that C₄-HSL does not play a significant role in biofilm formation.^{9,10} However, we have recently shown that strain PAO-BI bears the *nfxC* mutation.¹⁴ This mutation leads to overexpression of the MexEF-OprN multidrug efflux system, and to resistance towards quinolones, chloramphenicol, trimethoprim and tetracycline. More importantly, this mutation also leads to a reduction in *rhlI* expression, responsible for lower C₄-HSL production, compared with the non-*nfxC* wild-type PAO1 strain PT5.¹⁴ Therefore, we wondered whether the reduced expression of *rhlI* by strains PAO-BI and PAO-JP1 might have led to an underestimation of the role of C₄-HSL in biofilm formation. In accordance with a recent report,²⁴ we have shown that the *rhlI* mutant PDO100 formed slightly less biofilm compared with strain PAO-BI (Figure 1a). More importantly, strain PAO-BI only produced 60% of the total biofilm compared with wild-type PT5 (Figure 1a), suggesting that overexpression of the MexEF-OprN multidrug efflux system reduces the biofilm production of strain PAO-BI. In order to confirm this

result we deleted the *mexE* gene that encodes the membrane fusion protein of the MexEF-OprN efflux pump¹⁷ in strain PAO-BI to obtain mutant PT918. Such a deletion leads to complete inactivation of the MexEF-OprN efflux system, therefore suppressing the phenotype associated with pump overexpression.¹⁴ When tested in our static biofilm model, mutant PT918 was completely restored in biofilm formation to wild-type PT5 levels (Figure 1a). We also measured C₄-HSL production in culture supernatants of strains PT5, PAO-BI and PT918 by a specific bioassay. C₄-HSL production, reduced by 50% in strain PAO-BI, was restored to strain PT5 levels by the inactivation of the MexEF-OprN efflux system in strain PAO-BI (Table 2). These results confirm that the *nfxC* mutation is responsible for a reduction in biofilm formation by strain PAO-BI resulting from decreased C₄-HSL production.

In order to determine the role of C₄-HSL during biofilm formation, we decided to compare the total biofilm formed by wild-type PT5 and its derived *lasI* (PT466), *rhlI* (PT454), and *lasI/rhlI* (PT502) mutants. First, the production of C₄-HSL was measured in the culture supernatants of these mutants. Some reduction in C₄-HSL production can be expected in a *lasI* mutant as the *las* quorum-sensing system controls the transcription of *rhlR*, itself required for optimal C₄-HSL production.²⁶ Indeed the C₄-HSL production of the *lasI* mutant PT466 was reduced by 55% compared with its parent strain, probably as a result of the *las/rhl* hierarchy. The *lasI* mutant PAO-JP1 was even more severely affected and produced only 2.5% compared with its parent strain and 1.5% compared with strain PT5 (Table 2). As expected, culture supernatants of mutants PT454, PT502 and PDO100 contained no detectable C₄-HSL (Table 2).

When biofilm production was assessed, the *lasI* mutant PT466 produced slightly more biofilm than strain PT5 (Figure 1b). In contrast, the biofilm formed by the *rhlI* mutant PT454 was reduced by 70% compared with its parent strain (Figure 1b), correlating with the reduction in biofilm formed by the *rhlI* mutant PDO100 (Figure 1a). Furthermore, the double *lasI/rhlI* mutant PT502 formed a similar amount of biofilm as the *rhlI* mutant PT454 (Figure 1b). These results indicate that C₄-HSL is required for full biofilm formation. To confirm this hypothesis, we complemented mutant PT454 by adding exogenous C₄-HSL during the biofilm formation assay. As shown in Figure 1(b), addition of exogenous C₄-HSL partially restored the biofilm formation of *rhlI* mutant PT454 from 30% to 65% of the wild-type PT5 level. Similarly, in the presence of both exogenous AHLs, the biofilm formed by mutant PT502 increased from 30% to 75% of the PT5 level (Figure 1b). The lack of complete complementation of both mutants through addition of a constant concentration of exogenous autoinducers to the biofilm assay is likely to result from suboptimal AHL concentrations as these vary both in time and space during biofilm formation.¹⁰ We do not believe that secondary mutations in *vfr* and *algC* in our cell-to-cell signalling mutants could be responsible for the lack of complete complementation. Mutations in these genes affect twitching motility, which is cell-to-cell signalling independent.^{27,28} As twitching motility did not differ between parent strain PT5 and its derived cell-to-cell signalling mutants PT466, PT454 and PT502 (data not shown), such secondary mutations are unlikely to have occurred in our strains.

These results clearly demonstrate that, at least under our experimental conditions, C₄-HSL is required for optimal biofilm formation by *P. aeruginosa*. Indeed it appears that a previously undiscovered reduced expression of *rhlI*, leading to lower C₄-HSL production, in the wild-type strain PAO-BI, is responsible for an underestimation of the role of this autoinducer in biofilm formation. The importance of C₄-HSL is indeed not visible when PAO-BI is used as the control

Inhibition of cell-to-cell signalling by azithromycin




Figure 1. (a) Biofilm formation in wild-type *Pseudomonas aeruginosa* and AHL-deficient mutants. (b) Effects of AHLs on biofilm formation.

strain,⁹ or when carrying an *rhII* reporter fusion.¹⁰ In contrast, the importance of this autoinducer becomes apparent when both the parent and the *rhII* mutant do not overexpress the MexEF-OprN efflux system. These results correlate well with the recent observation that the *rhI* system is activated during the maturation stage of biofilm development.²⁹ It appears that while the *las* system (LasR/3-oxo- C_{12} -HSL) is essential for biofilm differentiation,⁹ and plays a role during the irreversible attachment stage,²⁹ the *rhI* system (RhIR/ C_4 -HSL) also plays an important role.

The finding that *P. aeruginosa* strains overexpressing the MexEF-OprN multidrug efflux system are impaired in biofilm formation is interesting. Such strains can be selected during quinolone treatment in an animal model,³⁰ and are less virulent in a rat model of acute pneumonia.³¹ Whether such multidrug-resistant isolates could be

selected during antimicrobial treatment of CF patients, and affect the evolution of the disease deserves further investigation.

Azithromycin inhibits biofilm formation by reducing cell-to-cell signalling


The potential clinical value of antibacterials that would control and/or prevent *P. aeruginosa* infections by interfering with cell-to-cell signalling has recently been underlined.^{2,32} The macrolide antibiotic azithromycin is neither bactericidal nor bacteriostatic against *P. aeruginosa* (MIC 64–128 mg/L) at achievable tissue concentrations (1–4 mg/L).^{33,34} However, even at low concentrations (1–2 mg/L) azithromycin reduced the adherence of *P. aeruginosa* to polystyrene,³⁵ as well as the production of exopolysaccharides by *P. aeruginosa*, and has therefore been suggested to inhibit biofilm

Table 2. Concentration of C₄-HSL in culture supernatants of *P. aeruginosa* cell-to-cell signalling mutants after 6 h of growth in LB medium

<i>P. aeruginosa</i> strains	C ₄ -HSL (µM)
PT5	10.24 ± 0.51
PT466 (<i>nfxCΔlasI</i>)	4.41 ± 1.6
PT454 (<i>ΔrhlI</i>)	<10 ⁻³
PT502 (<i>ΔlasI, ΔrhlI</i>)	<10 ⁻³
PAO-BI (<i>nfxC</i>)	5.57 ± 0.27
PAO-JP1 (<i>nfxC, ΔlasI</i>)	0.15 ± 0.02
PT918 (<i>nfxC, mexE</i>)	9.54 ± 0.31
PDO100 (<i>ΔrhlI</i>)	<10 ⁻³

formation.³⁶ We have recently shown that 2 mg/L azithromycin inhibits the production of both 3-oxo-C₁₂-HSL and C₄-HSL by *P. aeruginosa*.¹⁵ In view of the above presented results we wondered whether azithromycin inhibits biofilm formation by interfering with autoinducer synthesis. In the presence of 2 mg/L azithromycin, the biofilm formed by strain PT5 was reduced by 45% as quantified by Crystal Violet staining (Figure 2a). This decrease was associated with a 50% reduction in exopolysaccharide production as measured by the total carbohydrate assay. In contrast 2 mg/L azithromycin did not affect biofilm production by mutant PT502 (27% of wild-type in the absence versus 25% in the presence of 2 mg/L azithromycin), suggesting that azithromycin exerts its effect on biofilm formation via inhibition of cell-to-cell signalling.

In order to confirm that azithromycin reduced the production of both AHLs in the biofilm, we directly extracted and measured both AHLs from strain PT5 biofilms grown on PVC strips in the absence and presence of 2 mg/L azithromycin. As expected, both 3-oxo-C₁₂-HSL and C₄-HSL were severely reduced in the presence of the macrolide (Figure 2b). Addition of both AHLs in the presence of azithromycin restored the amount of biofilm formed to 85% of the initial levels observed in the absence of azithromycin as measured by Crystal Violet staining, and to 80% as measured by exopolysaccharide production (Figure 2a). Taken together, these results indicate that 2 mg/L azithromycin inhibits the production of biofilm by wild-type PT5 in our biofilm model at least partially by interfering with the production of the two autoinducers. As 3-oxo-C₁₂-HSL is required for biofilm differentiation,⁹ it is likely that azithromycin, by reducing both C₄-HSL and 3-oxo-C₁₂-HSL formation, leads not only to a reduction in the total amount of biofilm formed, but also affects its differentiation. It has been recently described that rhamnolipid surfactant is important for the maintenance of biofilm architecture by maintaining open channels within the biofilm structure.¹³ Moreover the *rhl* cell-to-cell signalling system has been suggested to protect *P. aeruginosa* strains growing inside biofilms by controlling the production of nitrite reductase essential for the detoxification from NO produced during growth in anaerobic conditions.¹² Both these functions are dependent on the adequate production of C₄-HSL.² It appears therefore that azithromycin by reducing cell-to-cell signal production not only reduces the production of extracellular virulence factors such as elastase,¹⁵ but also interferes with biofilm formation at different levels. This could be particularly useful in clinical situations, such as cystic fibrosis,^{4,11} and colonization of intubation devices in which growth in biofilm might play an important role. The

**Figure 2.** Effect of azithromycin on (a) biofilm formation, determined by Crystal Violet staining (diagonally striped bars) and exopolysaccharide production (white bars) and (b) AHL production.

recent encouraging results obtained in CF patients treated with azithromycin^{37–39} might therefore not only be the result of the suggested anti-inflammatory effect of this macrolide, but also because of its cell-to-cell signalling blocking activity. These results support the need for active research to develop more efficient cell-to-cell signalling blockers that could, according to the results presented here, reduce *P. aeruginosa* biofilm formation on medical devices such as endotracheal intubation devices.

Acknowledgements

Synthetic 3-oxo-C₁₂-HSL and C₄-HSL were kindly provided by U. Burger, Department of Chemistry, University of Geneva. We would like to thank R. Comte for outstanding technical assistance and P. Wood for carefully reviewing the manuscript prior to submission. This work was supported by a grant from the Programme Commun de Recherche en Génie Biomédical Genève Lausanne 1999–2002 (to C.V.D.), and grants 3231-051940.97 and 3200-052189.97 from the Swiss National Research Foundation (to C.V.D.).

References

1. Costerton, J. W., Stewart, P. S. & Greenberg, E. P. (1999). Bacterial biofilms: a common cause of persistent infections. *Science* **284**, 1318–22.
2. Van Delden, C. & Igleski, B. H. (1998). Cell-to-cell signaling and *Pseudomonas aeruginosa* infections. *Emerging Infectious Diseases* **4**, 551–60.
3. Geisenberger, O., Givskov, M., Riedel, K. *et al.* (2000). Production of *N*-acyl-L-homoserine lactones by *P. aeruginosa* isolates from chronic lung infections associated with cystic fibrosis. *FEMS Microbiology Letters* **184**, 273–8.
4. Singh, P. K., Schaefer, A. L., Parsek, M. R. *et al.* (2000). Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. *Nature* **407**, 762–4.
5. Wu, H., Song, Z., Hentzer, M. *et al.* (2000). Detection of *N*-acylhomoserine lactones in lung tissues of mice infected with *Pseudomonas aeruginosa*. *Microbiology* **146**, 2481–93.
6. Stickler, D. J., Morris, N. S., McLean, R. J. *et al.* (1998). Biofilms on indwelling urethral catheters produce quorum-sensing signal molecules *in situ* and *in vitro*. *Applied and Environmental Microbiology* **64**, 3486–90.
7. Middleton, B., Rodgers, H. C., Camara, M. *et al.* (2002). Direct detection of *N*-acylhomoserine lactones in cystic fibrosis sputum. *FEMS Microbiology Letters* **207**, 1–7.
8. Erickson, D. L., Endersby, R., Kirkham, A. *et al.* (2002). *Pseudomonas aeruginosa* quorum-sensing systems may control virulence factor expression in the lungs of patients with cystic fibrosis. *Infection and Immunity* **70**, 1783–90.
9. Davies, D. G., Parsek, M. R., Pearson, J. P. *et al.* (1998). The involvement of cell-to-cell signals in the development of a bacterial biofilm. *Science* **280**, 295–8.
10. De Kievit, T. R., Gillis, R., Marx, S. *et al.* (2001). Quorum-sensing genes in *Pseudomonas aeruginosa* biofilms: their role and expression patterns. *Applied and Environmental Microbiology* **67**, 1865–73.
11. Favre-Bonte, S., Pache, J. C., Robert, J. *et al.* (2002). Detection of *Pseudomonas aeruginosa* cell-to-cell signals in lung tissue of cystic fibrosis patients. *Microbial Pathogenesis* **32**, 143–7.
12. Yoon, S. S., Hennigan, R. F., Hilliard, G. M. *et al.* (2002). *Pseudomonas aeruginosa* anaerobic respiration in biofilms: relationships to cystic fibrosis pathogenesis. *Developmental Cell* **3**, 593–603.
13. Davey, M. E., Caiazza, N. C. & O'Toole, G. A. (2003). Rhamnolipid surfactant production affects biofilm architecture in *Pseudomonas aeruginosa* PAO1. *Journal of Bacteriology* **185**, 1027–36.
14. Kohler, T., Van Delden, C., Curty, L. K. *et al.* (2001). Overexpression of the MexEF-OprN multidrug efflux system affects cell-to-cell signaling in *Pseudomonas aeruginosa*. *Journal of Bacteriology* **183**, 5213–22.
15. Tateda, K., Comte, R., Pechere, J. C. *et al.* (2001). Azithromycin inhibits quorum sensing in *Pseudomonas aeruginosa*. *Antimicrobial Agents and Chemotherapy* **45**, 1930–3.
16. Terry, J. M., Pina, S. E. & Mattingly, S. J. (1992). Role of energy metabolism in conversion of nonmucoid *Pseudomonas aeruginosa* to the mucoid phenotype. *Infection and Immunity* **60**, 1329–35.
17. Kohler, T., Michea-Hamzehpour, M., Henze, U. *et al.* (1997). Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of *Pseudomonas aeruginosa*. *Molecular Microbiology* **23**, 345–54.
18. Kohler, T., Curty, L. K., Barja, F. *et al.* (2000). Swarming of *Pseudomonas aeruginosa* is dependent on cell-to-cell signaling and requires flagella and pili. *Journal of Bacteriology* **182**, 5990–6.
19. Van Delden, C., Comte, R. & Bally, A. M. (2001). Stringent response activates quorum sensing and modulates cell density-dependent gene expression in *Pseudomonas aeruginosa*. *Journal of Bacteriology* **183**, 5376–84.
20. Miller, J. H. (1972). *Experiments in Molecular Genetics*, pp. 352–355. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.
21. Takeoka, K., Ichimiya, T., Yamasaki, T. *et al.* (1998). The *in vitro* effect of macrolides on the interaction of human polymorphonuclear leukocytes with *Pseudomonas aeruginosa* in biofilm. *Chemotherapy* **44**, 190–7.
22. O'Toole, G. A. & Kolter, R. (1998). Flagellar and twitching motility are necessary for *Pseudomonas aeruginosa* biofilm development. *Molecular Microbiology* **30**, 295–304.
23. Kintner, P. K. & Van Buren, J. P. (1982). Carbohydrate interference and its correction in pectin analysis using the m-hydroxydiphenyl method. *Journal of Food Science* **47**, 756–64.
24. Shih, P. C. & Huang, C. T. (2002). Effects of quorum-sensing deficiency on *Pseudomonas aeruginosa* biofilm formation and antibiotic resistance. *Journal of Antimicrobial Chemotherapy* **49**, 309–14.
25. Heydorn, A., Ersboll, B., Kato, J. *et al.* (2002). Statistical analysis of *Pseudomonas aeruginosa* biofilm development: impact of mutations in genes involved in twitching motility, cell-to-cell signaling, and stationary-phase sigma factor expression. *Applied and Environmental Microbiology* **68**, 2008–17.
26. Latifi, A., Foglino, M., Tanaka, K. *et al.* (1996). A hierarchical quorum-sensing cascade in *Pseudomonas aeruginosa* links the transcriptional activators LasR and RhIR (VsmR) to expression of the stationary-phase sigma factor RpoS. *Molecular Microbiology* **21**, 1137–46.
27. Beatson, S. A., Whitchurch, C. B., Semmler, A. B. T. *et al.* (2002). Quorum sensing is not required for twitching motility in *Pseudomonas aeruginosa*. *Journal of Bacteriology* **184**, 3598–604.
28. Beatson, S. A., Whitchurch, C. B., Sargent, J. L. *et al.* (2002). Differential regulation of twitching motility and elastase production by Vfr in *Pseudomonas aeruginosa*. *Journal of Bacteriology* **184**, 3605–13.
29. Sauer, K., Camper, A. K., Ehrlich, G. D. *et al.* (2002). *Pseudomonas aeruginosa* displays multiple phenotypes during development as a biofilm. *Journal of Bacteriology* **184**, 1140–54.
30. Join-Lambert, O. F., Michea-Hamzehpour, M., Kohler, T. *et al.* (2001). Differential selection of multidrug efflux mutants by trovafloxacin and ciprofloxacin in an experimental model of *Pseudomonas aeruginosa* acute pneumonia in rats. *Antimicrobial Agents and Chemotherapy* **45**, 571–6.
31. Cosson, P., Zulianello, L., Join-Lambert, O. *et al.* (2002). *Pseudomonas aeruginosa* virulence analyzed in a *Dictyostelium discoideum* host system. *Journal of Bacteriology* **184**, 3027–33.
32. Hassett, D. J., Cuppoletti, J., Trapnell, B. *et al.* (2002). Anaerobic metabolism and quorum sensing by *Pseudomonas aeruginosa* biofilms in chronically infected cystic fibrosis airways: rethinking antibiotic treatment strategies and drug targets. *Advanced Drug Delivery Reviews* **54**, 1425–43.
33. Retsema, J., Girard, A., Schelkly, W. *et al.* (1987). Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. *Antimicrobial Agents and Chemotherapy* **31**, 1939–47.
34. Kucers, A., Crowe, S. M., Grayson, M. L. *et al.* (1997). Azithromycin. In *The Use of Antibiotics*, pp. 653–663. Butterworth-Heinemann, Oxford, UK.
35. Vranes, J. (2000). Effect of subminimal inhibitory concentrations of azithromycin on adherence of *Pseudomonas aeruginosa* to polystyrene. *Journal of Chemotherapy* **12**, 280–5.
36. Ichimiya, T., Takeoka, K., Hiramatsu, K. *et al.* (1996). The influence of azithromycin on the biofilm formation of *Pseudomonas aeruginosa* *in vitro*. *Chemotherapy* **42**, 186–91.
37. Jaffe, A., Francis, J., Rosenthal, M. *et al.* (1998). Long-term azithromycin may improve lung function in children with cystic fibrosis. *Lancet* **351**, 420.
38. Wolter, J., Seeney, S., Bell, S. *et al.* (2002). Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. *Thorax* **57**, 212–6.
39. Equi, A., Balfour-Lynn, I. M., Bush, A. *et al.* (2002). Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. *Lancet* **360**, 978–84.

40. Seed, P. C., Passador, L. & Iglewski, B. H. (1995). Activation of the *Pseudomonas aeruginosa lasI* gene by LasR and the *Pseudomonas autoinducer* PAI: an autoinduction regulatory hierarchy. *Journal of Bacteriology* **177**, 654–9.
41. Pearson, J. P., Pesci, E. C. & Iglewski, B. H. (1997). Role of *Pseudomonas aeruginosa las* and *rhl* quorum-sensing systems in the control of elastase and rhamnolipid biosynthesis genes. *Journal of Bacteriology* **179**, 5756–67.
42. Brint, J. M. & Ohman, D. E. (1995). Synthesis of multiple exoproducts in *Pseudomonas aeruginosa* is under the control of RhlR-RhlI, another set of regulators in strain PAO1 with homology to the autoinducer-responsive LuxR-LuxI family. *Journal of Bacteriology* **177**, 7155–63.